Vaccinia Virus and Immune Checkpoint Inhibitors: A Viable Combination in Advanced RCC?
Initial data from a phase 1b trial shows encouraging results.
Urologic Cancers
UROLOGIC CANCER ADVISOR
FEATURED CONTENT
-
-
Genomics Industry Tries New Strategies to Engage Community Oncologists
Streamlined prescribing and reimbursement, patient education tools aim to overcome barriers to adoption of genetic testing. -
A New Look at the Dose-Response Relationship in Phase 1 Oncology Trials
The new generation of cancer drugs behave quite differently than cytotoxic therapies, and that may mean phase 1 trials need to be updated. -
Researchers Turn to Crowdsourcing to Learn More About COVID-19 and Cancer
Pooling data from physicians and patients appears to be an efficient way to answer urgent questions. -
Thyroid Dysfunction During Anti–PD‐1 Immunotherapy Linked to Better Survival Outcomes
There was no increase in survival linked to acquired subclinical thyroid dysfunction or preexisting thyroid dysfunction, however.
UROLOGIC CANCERS NEWS
Avelumab Shown to Prolong Survival in Advanced Urothelial Carcinoma
Pembrolizumab-Axitinib Continued to Offer Durable Benefits in Advanced RCC
Savolitinib Shows “Encouraging Efficacy” in MET-Driven Papillary RCC
Pembrolizumab Benefits Durable in BCG-Unresponsive High-Risk NMIBC
Pathologic Stage at RNU Predicts Oncologic Outcomes in High-Grade UTUC
Want to read more?
Please login or register first to view this content.
Next post in Urologic Cancers
